

10TH ANNUAL

Make The Best Of It Bash



PLEASE JOIN US

Friday, June 23, 2023

7:00 PM TO 10:00 PM

TROPICANA CASINO RESORT

2831 Boardwalk ♥ Atlantic City, NJ 08401



ENJOY AN EVENING OF SPECTACULAR

Cocktails & Hors D'Oeuvres

AMAZING SILENT AUCTION & AFTER PARTY

Past highlights include dinner with Philadelphia Eagles, tickets to Andy Cohen Live, vacations around the world and more.

To celebrate 10 years, feel free to wear something pink!

TICKET & SPONSORSHIP INFORMATION ON NEXT PAGE

You can also purchase sponsorships, buy tickets, book discounted hotel rooms, view and bid on auction items and learn more at

taramillerfoundation.org



The Tara Miller Melanoma Foundation Funded...

Dr. Arjun Raj from Penn Engineering who developed single cell sequencing technology to **identify why patients develop resistance to targeted therapies.**

[Click here to read the article](#)

TARA MILLER MELANOMA FOUNDATION 10TH ANNUAL BASH KINDLY RSVP BY MAY 25, 2023

PRESENTING SPONSORSHIP AVAILABLE UPON REQUEST

- DIAMOND SPONSOR \$25,000**
 - 10 Sponsor Tickets
 - Website Recognition
 - Social Media Recognition
 - Logo on Screens & Included in Signage at Event
 - Included in Eblast
 - Included in Press Release
 - Logo on Step & Repeat
 - Verbal Recognition at Event
 - Logo on Advertisements
 - Program Book Inside Cover (8"x10.5")

- PLATINUM SPONSOR \$15,000**
 - 10 Sponsor Tickets
 - Website Recognition
 - Logo on Screens & Included in Signage at Event
 - Social Media Recognition
 - Included in Eblast
 - Full Pg. Program Book Ad (8"x10.5")

- GOLD SPONSOR \$10,000**
 - 10 Sponsor Tickets
 - Website Recognition
 - Social Media Recognition
 - Included in Eblast
 - Logo on Screens at Event
 - Full Pg. Program Book Ad (8"x10.5")

- SILVER SPONSOR \$5,000**
 - 10 Sponsor Tickets
 - Website Recognition
 - Full Pg. Program Book Ad (8"x10.5")

- BRONZE SPONSOR \$2,500**
 - 10 Sponsor Tickets
 - Website Recognition
 - Logo on Screens at Event
 - Full Pg. Program Book Ad (8"x10.5")

PROGRAM BOOK AD - PLEASE INDICATE AD SIZE

- FULL PAGE: \$1,000**
8"x10.5"
- HALF PAGE: \$500**
8"x5.25"
- QUARTER PAGE: \$300**
4"x5.25"

Submit all logos for sponsorship packets to info@taramillerfoundation.org.

- Yes, I would like to be a _____ sponsor, enclosed is my check for \$_____.
- Yes, I can attend, please reserve _____ ticket(s) at \$150 per person.
- No, I am unable to attend. Please accept my donation of \$_____.
- Please place an Ad in your program book, enclosed is my check for \$_____.



Name _____

Address _____

City _____ State _____ Zip _____

Email _____

Name as you would like it to be listed: _____

MAKE CHECK PAYABLE TO: Tara Miller Melanoma Foundation
P.O. Box 3154, Margate, NJ 08402

Please submit artwork for your Ad in 300dpi PDF file format by **May 25, 2023**.

EMAIL: info@taramillerfoundation.org

Celebrating 10 Years



Ten years ago, Tara started this foundation. While she was fiercely fighting her own battle with melanoma, she had the vision and selflessness to want to champion research knowing it likely would not change her own odds. At only 29 years old, she wanted her own experiences with melanoma to help others. At the time she said:

“According to statistics 75% of Stage 4 melanoma patients like myself are dead within a year of their diagnosis — I was diagnosed 11 months ago and even after having somewhere around 14 brain tumors — yes I lost count — I know that those aren’t good odds. I can’t control those statistics, but part of making the best of it is accepting what I can’t control and focusing on what I can control. So, although we can’t change what the statistics on melanoma have been, we chose to make the best of it and try to help change where they are going.”

— Tara Miller (June 2014)

Tara died 6 months after the first Make The Best Of It Bash, just six weeks shy of her 30th birthday. She made it clear no matter what her outcome was, she wanted us to wholeheartedly continue her mission to change the odds for the patients that would come after her and eventually, fund the research that would find a cure for this devastating disease.

Over the last 10 years with the help of our generous community we have funded over \$6.4 million to help advance melanoma research. Together, we have made incredible progress in this fight - we HAVE changed the odds.



CHAIRPERSONS DEBBIE & GEORGE MILLER AND COMMITTEE MEMBERS

Patti & John Albright | Kate Athmer & Rob Johnson | Megan Bannigan Ott & Mike Ott | Remy Berger
Mandi & Robert Bray | Mickey & Dave Coskey | John D'Angelo | Michael D'Angelo | Angel & Jerome DiPentino
Cara & Pat Duffner | Enita & Joe Dugan | Tom Enstice | Fran Epstein | Elizabeth & Andrew Feriozzi
Rebecca & Tom Firmani | Carol & Guy Giordano | Giulia & Greg Skoutelas | Justine Giordano & Chip Holston
Kathleen & Vincent Giordano | Joanne Goldberg & Janey Steinmetz | Isabel Halpin | Wendy Hamilton
Patrick Hardy & Stephen Dahlan | Stephanie & William Hughes Jr. | Chase Hutt | Rachel & Drew Katz
Caroline & Greg Gilroy | Sarah & Daniel Keating | Patrick V. Larkin Jr. | Susan & Pat Larkin | Denise & Erin Maher
Janet Markowitz & Chris Tortu | Debbie & George Miller | Kristi Miller | Lauren Miller Parker & Josh Parker
Robyn & Tom Musi | Jennifer & Chris Myers | Anne, Julie & Katie Neustadter | Jason Nika | Likie & George Nika
Danielle Palladino | Margie & Jack Plackter | Carolyn & Vince Polistina | Francesca Santoro
The Honorable John Schultz & Gary Hill | Niki Shaffer | Erin Sykes | Gary Turner & Dave Sawyer
Pam & Tony Tyson | Jamie & Kevin Walker | Geri & Glen Zuck

Our Inspiration



“ One of the hardest parts about having cancer is that you have no control over it; I cannot control how my body will respond, what my scans show or how to stop the disease from spreading. However, I can control how I chose to deal with these obstacles. I have chosen to find the #silverlinings and #makethbestofit and that is exactly what we hope to do with the Tara Miller Melanoma Foundation. Hopefully one day we will get to see the money raised by this Foundation making a difference in someone else’s fight against this terrible disease. ”

— Tara Miller (2014)

Five years ago, we met one of those “someone else’s” that had a different outcome because of the research funded....

Quote From A Patient:

“ I was diagnosed with advanced stage Melanoma in 2018 and because of Tara and her mission to fund groundbreaking research, I had better treatments available. TMMF improved my odds and thanks to the foundation and its supporters, I am alive today, celebrating 5 years survival. I am forever grateful for Tara, her family and the TMMF community. ”

— Danielle P. (age 39)

The number of people who were moved by Tara’s courage and her character is second only to the number of lives that will be forever changed by her legacy. Tara made sure to leave patients and families experiencing melanoma with a cause for hope, and it is your generous support that allows us to continue to forge ahead and fulfill the charge Tara herself gave us to cure melanoma. We remember her determined spirit, which remains at the heart of every clinical breakthrough and innovative research accomplishment that will now be published from a cancer center that proudly holds her name.



— Dr. Bob Vonderheide,
Director of
Abramson
Cancer Center

Celebrating 10 Years of Hope & Progress

OVER \$6.4 MILLION

funded to melanoma research



55 PROJECTS
selected & funded.



Funded projects at
8 OF THE TOP
melanoma research
institutes in the world.



20 CLINICAL TRIALS
funded including first of its kind
clinical trial for CAR T-cell therapy
in melanoma targeting the protein
cMET.



50+
50+ RESEARCHERS
working to find a
cure with TMMF
funding.



CONTRIBUTED TO 58 PUBLISHED STUDIES INCLUDING:

- Groundbreaking RadVax trial combining radiation to immunotherapy treatments to enhance a patient's response.
- Penn Engineering team who developed single cell sequencing technology to identify why patients develop resistance to targeted therapies.
- Identification of a new target for melanoma therapy AND the development of a new drug to attack that target.
- Changing the way that oncologists treat melanoma by studying patients', including Tara's, blood and tumor samples that demonstrated patient's immune systems response after just one dose of PD1 therapy.



15 FDA APPROVALS
since 2014.



30 OTHER CANCERS BENEFITING
from the
breakthroughs in
melanoma including
Immunotherapy
treatments which
was first pioneered
in melanoma.



50% OF LATE STAGE PATIENTS
are now responding
to treatment and
living more than a
year - compared to
only 20% in 2014.



100% OF ALL MONEY RAISED
goes directly to
research.

In reflecting on these past 10 years, the progress in melanoma treatment is beyond my imagination. We are truly changing the trajectory of the disease for an individual patient while at the same time learning new ways and finding new treatments that can benefit so many, many patients. Tara continues to galvanize our work every day to cure melanoma.

— Dr. Lynn Schuchter, MD at Abramson Cancer Center



\$6,428,000 FUNDED TO MELANOMA RESEARCH!

\$5,003,000 Funded to Research
at Penn Abramson Cancer Center Melanoma Program

Taking Novel Approaches

\$1,963,000

17 cutting-edge projects funded to think outside the box and attack melanoma in innovative ways like: developing a melanoma vaccine, applying CAR T-cell technology to melanoma, using copper-binding to kill BRAF-mutated melanoma cells, and developing new imaging tools to better track melanoma tumor growth.

Predicting Response

\$1,400,000

12 projects that have changed the way physicians treat melanoma. This includes the groundbreaking published studies in which Tara's own samples were used to determine how quickly patients respond to immunotherapy, a clinical trial offering those immunotherapy treatments to high risk stage 2 patients to prevent recurrence, and studying the impact of the microbiome on patients' response to immunotherapy.

Understanding Melanoma Metastasis

\$615,000

Seven projects funded to tackle the biggest obstacles in melanoma treatment. Researchers explored the unique cells of the brain and why they help melanoma cells grow, the role of the lymphatic system in allowing melanoma cells to spread beyond the lymph nodes, and how liquid biopsies can provide an early warning system before metastasis occurs.

Overcoming Resistance

\$600,000

Six projects funded to address one of the consistent challenges for melanoma patients undergoing treatment. Researchers developed a brand new "barcoding" technology to identify which individual cells become resistant and also developed a new drug to inhibit a cell process that allows them to become resistant.

Employing Combination Therapies

\$425,000

Four projects funded to enhance patient response to therapy by pairing multiple therapies together to make them more effective and durable. In addition to combining multiple effective checkpoint inhibitors, researchers led a clinical trial adding radiation therapy to the drug combination and found that it jump-started the immune system and increased patient response.

\$1,425,000 Funded to Melanoma Research Alliance Young Investigators

as part of Team Science Awards that foster collaboration across the field

2022 Inna Smalley, H. Lee Moffitt Cancer Center, Tumor-Stroma Metabolic Crosstalk in Melanoma Brain Metastases

2021 Benjamin Izar, Columbia University, Dissecting the role of CD58 in cancer immune evasion and T-cell exclusion

2020 Michael Pacold, New York University School of Medicine, Targeting 1-Carbon Metabolism in Melanoma Brain Metastases

2019 Russell Jenkins, Massachusetts General Hospital, TANK-Binding Kinase 1 (TBK1) As A Novel Cancer Immunotherapy Target

2018 A. Hunter Shain, University of California, San Francisco, The Genomic Landscape of Individual Melanocytes from Human Skin

2017 Kunal Rai, University of Texas MD Anderson Cancer Center, Epigenetic Effectors of Responses to Immune Checkpoint Blockade Agents

2016 Yuval Tabach, Hebrew University of Jerusalem, Identification of Novel Regulators of Melanoma Brain Metastasis

2015 Tara (Gangadhar) Mitchell, University of Pennsylvania and Christina Twyman-Saint Victor, University of Pennsylvania, Radiation and Immune Checkpoint Blockade from Mechanism to Patients



The Tara Miller Melanoma Foundation Funded...

Research by Dr. Ravi Amaravadi, now the Associate Director for Translational Research for the Abramson Cancer Center, which led not only to the **identification of a new target for melanoma therapy** but also the **development of a new drug to attack that target.**

[Click here to read the article](#)